Healthequity (HQY) Cost of Revenue (2016 - 2026)
Healthequity has reported Cost of Revenue over the past 14 years, most recently at -$198.6 million for Q1 2026.
- For Q1 2026, Cost of Revenue fell 155.98% year-over-year to -$198.6 million; the TTM value through Jan 2026 reached $25.5 million, down 94.88%, while the annual FY2026 figure was $95.2 million, 77.46% down from the prior year.
- Cost of Revenue for Q1 2026 was -$198.6 million at Healthequity, down from $24.4 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $354.9 million in Q1 2025 and troughed at -$198.6 million in Q1 2026.
- A 5-year average of $67.7 million and a median of $88.8 million in 2022 define the central range for Cost of Revenue.
- Biggest five-year swings in Cost of Revenue: soared 403.93% in 2024 and later tumbled 155.98% in 2026.
- Year by year, Cost of Revenue stood at $88.8 million in 2022, then plummeted by 77.86% to $19.7 million in 2023, then rose by 15.16% to $22.6 million in 2024, then increased by 7.84% to $24.4 million in 2025, then plummeted by 913.71% to -$198.6 million in 2026.
- Business Quant data shows Cost of Revenue for HQY at -$198.6 million in Q1 2026, $24.4 million in Q4 2025, and $93.2 million in Q3 2025.